Back to Journals » Cancer Management and Research » Volume 12

Cell Differentiation Agent-2 (CDA-2) Inhibits the Growth and Migration of Saos-2 Cells via miR-124/MAPK1

Authors Li Q, Li G, Liu C, Chen N, Deng B, Xie Y

Received 8 February 2020

Accepted for publication 15 May 2020

Published 15 June 2020 Volume 2020:12 Pages 4541—4548


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan

Quanxiu Li,1 Guangchun Li,1 Changyi Liu,1 Na Chen,2 Bangyu Deng,3 Youke Xie4

1Department of Orthopedics, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, People’s Republic of China; 2Department of Pathology, Guangdong Women and Children Hospital, Guangzhou, Guangdong, People’s Republic of China; 3Department of Oncology, Affiliated Tumor Hospital of Guangzhou University, Guangzhou, Guangdong, People’s Republic of China; 4Department of Oncology, Hospital of Ruikang Affiliated to Guangxi University of Chinese Medicine, Guangxi, People’s Republic of China

Correspondence: Quanxiu Li Email

Background: CDA-2 (cell differentiation agent 2), isolated from healthy human urine, exerts antitumor effects in multiple types of cancer cells. However, its role in osteosarcoma has not been studied.
Methods: The MTT assay was used to examine the cell proliferation rate. A colony formation assay was used to examine cell growth. The Transwell assay was used to examine cell migration ability. A real-time PCR assay was used to examine the expression levels of miR-124 and MAPK1. A Western blot assay was used to examine protein expression levels. MAPK1 was selected as a possible target of miR-124, and the targeting relationship was examined by a luciferase reporter assay.
Results: We revealed that CDA-2 decreased the growth, migration and invasion ability of the osteosarcoma cell line Saos-2. Further study revealed that CDA-2 elevated the expression level of miR-124. MAPK1 was identified as a downstream target of miR-124. Knockdown of miR-124 or overexpression of MAPK1 counteracted CDA-2’s effects on cell growth and invasion.
Conclusion: Our data revealed that the miR-124/MAPK1 axis mediated CDA-2’s function in Saos-2 cells. CDA-2 can be used as a new treatment strategy for osteosarcoma.

Keywords: cell differentiation agent 2, osteosarcoma, miR-124, MAPK1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]